ClearPoint Neuro
CLPT
71 hedge funds and large institutions have $42.7M invested in ClearPoint Neuro in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 6 closing their positions.
783% more call options, than puts
Call options by funds: $671K | Put options by funds: $76K
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
43% more capital invested
Capital invested by funds: $29.8M → $42.7M (+$12.9M)
13% more funds holding
Funds holding: 63 → 71 (+8)
1.44% more ownership
Funds ownership: 24.13% → 25.57% (+1.4%)
0% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 18
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$599K |
| 2 |
RA
Royce & Associates
New York
|
+$300K |
| 3 |
CWM
Cahill Wealth Management
Portage,
Michigan
|
+$250K |
| 4 |
Morgan Stanley
New York
|
+$245K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$329K |
| 2 |
MC
Mayo Clinic
Rochester,
Minnesota
|
-$191K |
| 3 |
SG Americas Securities
New York
|
-$83K |
| 4 |
JP Morgan Chase
New York
|
-$58.8K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$52.6K |
CLPT Hedge Fund Activity: Q4 2023 in Review
71 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in ClearPoint Neuro (CLPT) for Q4 2023, worth a combined $42.7M — up 43% from $29.8M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new CLPT positions and 6 closed out — a net gain of 8 holders — while 18 added to existing stakes and 18 trimmed.
The largest buyer was BlackRock, adding an estimated $599K. The largest seller was Citadel Advisors, cutting an estimated $329K.
- 71 institutional investors held ClearPoint Neuro (CLPT) as of Q4 2023, up from 63 in Q3 2023.
- Funds reported $42.7M of ClearPoint Neuro stock for Q4 2023, up 43% quarter-over-quarter.
- 14 funds opened new ClearPoint Neuro positions in Q4 2023 and 6 closed out, a net change of +8 holders.
- The largest ClearPoint Neuro buyer in Q4 2023 was BlackRock, an estimated $599K added.
- The largest ClearPoint Neuro seller in Q4 2023 was Citadel Advisors, an estimated $329K sold.
Based on aggregated 13F filings for Q4 2023.